RxDoctor Payments Data

Denise Keene, APRN

Psychiatric/Mental Health · Forest Hill, TXNPI 1457830770

Payments from drug & device makers

$3,484in general payments, 2019–2025

Across 196 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$705
  • Neurocrine Biosciences, Inc.$428
  • E.r. Squibb & Sons, L.L.C.$421
  • AbbVie$379
  • Johnson & Johnson$363
  • Indivior Inc.$288
  • plus $900 from 6 others

What the payments were for

  • Food & beverage$3,17591%
  • Education$3099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,484 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$9,312
Medicare patients
43
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate94$279,906
IngrezzaValbenazine Tosylate20$158,839
Invega TrinzaPaliperidone Palmitate12$117,300
Abilify MaintenaAripiprazole38$112,909
AustedoDeutetrabenazine11$67,146
AristadaAripiprazole Lauroxil22$63,086
Lurasidone Hcl55$23,355
RexultiBrexpiprazole13$18,299
Aripiprazole154$16,058
Clozapine43$7,417
Oxcarbazepine61$5,357
Venlafaxine Hcl ErVenlafaxine Hcl92$3,232
Divalproex Sodium93$3,205
Perphenazine54$3,019
Quetiapine Fumarate154$2,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$363$397,205106 claims
Neurocrine Biosciences, Inc.Ingrezza$428$158,83920 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$121$131,20751 claims
Teva Pharmaceuticals USA, Inc.Austedo$705$67,14611 claims
Alkermes, Inc.Aristada$234$63,08622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Forest Hill

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →